KCT0001897
Completed
未知
The Pilot Study on the Efficacy and Safety of Acupuncture and Analgesics against Cancer Pain in Advanced Cancer Patients
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dankook University
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age 19\-80
- •2\. Advanced cancer stage with only palliative treatments available
- •3\. Analgesic medication due to cancer pain
- •4\. Eastern Cooperative Oncology Group performance status 0\-2
- •5\. Life expectancy more than 6 months
- •6\. Voluntary agreement with the study protocols
Exclusion Criteria
- •1\. Hypersensitivity reaction after acupuncture
- •2\. Pregnant or breast\-feedingwoman, expectant mother
- •3\. The protocol writting or hospital visits deemed to be hard
- •4\. Other finds by Investigators are inadequate for the the clinical protocols
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Evaluation of the effectiveness and safety of acupoint pressure stimulation paste in preventing urinary retention after laparoscopic cholecystectomyaparoscopic cholecystectomyITMCTR2200006494Department of biliary tract sugery, West China Hospital of Sichuan University
Recruiting
Not Applicable
A pilot study of efficacy and safety of aprepitant with chemoradiotherapy involving weekly cisplatin in patients with cervical cancer.cervical cancerJPRN-UMIN000003979ara Medical University30
Active, not recruiting
Phase 1
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005317-68-BEAcerta Pharma, BV60
Active, not recruiting
Phase 1
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005317-68-GBAcerta Pharma B.V.60
Active, not recruiting
Phase 1
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-005317-68-ESAcerta Pharma, BV80